Beeline Medicines Corporation, a clinical-stage biotechnology company headquartered in Stamford, Connecticut, has publicly debuted with a USD 300 million Series A financing round to advance a portfolio of precision therapies targeting autoimmune and inflammatory diseases. The round was led by Bain Capital and closed in July 2025, when the company was formed, though Beeline Medicines only announced its public launch in April 2026.
The company's entire pipeline originates from an in-licensing agreement with Bristol Myers Squibb (NYSE: BMY), structured at the company's inception and covering five mechanistically selective therapeutic candidates spanning small molecules and biologics. Financial terms of the licensing arrangement have not been disclosed. The Series A proceeds are intended to fund operations through late-stage clinical development, the company said.
The lead asset, afimetoran, is a once-daily oral small molecule that equipotently inhibits TLR7 and TLR8 — innate immune receptors implicated in the aberrant type I interferon signaling that drives lupus pathology. The US FDA granted afimetoran Fast Track Designation for systemic lupus erythematosus (SLE) in May 2025, following Phase Ib proof-of-concept data in cutaneous lupus erythematosus. A Phase II trial in SLE is ongoing and expected to complete in the second half of 2026, after which Beeline Medicines intends to initiate a pivotal development program.